Novel Multispecific Nanobody Targeting CD3 Complex and DLL3 for Innovative Cancer Therapy
VHH-P712 represents a groundbreaking humanized nanobody biotherapeutic in biological testing, designed for the targeted treatment of cancer. This advanced construct simultaneously targets CD3 Complex (T Cell Receptor Complex) and delta like canonical Notch ligand 3 (DLL3), two pivotal molecules implicated in tumor progression and immune modulation. By engaging both CD3 Complex (T Cell Receptor Complex) found on T cells and DLL3, which is overexpressed in various malignancies, VHH-P712 offers a dual attack strategy against cancer. Its unique architecture and dual-targeting mechanism provide a new avenue for modulating the immune response and tumor microenvironment, highlighting its transformative potential in the oncology pipeline.
| Candidate | VHH-P712 |
| Target | CD3 Complex (T Cell Receptor Complex) delta like canonical Notch ligand 3 (DLL3) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P712 is currently open for out-licensing opportunities and strategic collaborations. Partners interested in advancing innovative multispecific immunotherapies for cancer are welcome to engage in co-development or licensing discussions.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P712 |
Modality
VHH-P712 adopts a multispecific nanobody modality composed of two chains, each ingeniously engineered for precise multivalent engagement. The first chain integrates single domain antibodies specific to DLL3 and an anti-CD3 VH domain, all connected via flexible (G4S)3 linkers and paired with a heterodimeric Fc knob. The second chain provides the complementary heterodimeric Fc hole, a further anti-CD3 VL domain, and additional linker architecture. The nanobody’s compact single-domain structure imparts superior tissue penetration, target accessibility, and enhanced stability compared to conventional antibodies. These characteristics enable more effective infiltration and action within solid tumors, presenting significant advantages in the context of cancer therapy.
Target
CD3 Complex and DLL3 are central to the mechanism of VHH-P712. CD3 Complex, a fundamental part of the T-cell receptor assembly, orchestrates immune cell activation and signaling, and is predominantly expressed on mature T lymphocytes. DLL3 is an inhibitory ligand in the Notch signaling pathway, abnormally overexpressed in several tumor types while largely absent from most adult tissues. CD3 Complex serves as a powerful trigger to recruit and activate cytotoxic T cells, while DLL3 provides a highly selective tumor marker. The dual targeting of CD3 Complex and DLL3 by VHH-P712 enhances both the specificity and potency of tumor cell clearance, establishing its strategic significance in cancer immunotherapy and marking it as a next-generation asset in oncology development.
Mechanism of Action
VHH-P712 exerts its antitumor effects through a dual-targeting mechanism. By binding to CD3 Complex on T lymphocytes and DLL3 on tumor cells, it forms a molecular bridge that facilitates immune synapse formation and targeted cytotoxicity. This engagement leads to the recruitment and activation of T cells specifically at DLL3-expressing tumor sites, promoting tumor cell lysis through signal transduction modulation. The nanobody platform allows for additional functionalities, such as the potential generation of antibody-drug conjugates or bispecific antibodies, broadening its therapeutic utility. Through precise molecular recognition, VHH-P712 capitalizes on both immune cell activation and tumor-associated antigen targeting, offering an innovative approach to cancer immunotherapy.
Cancer
Cancer remains the leading global health burden, with rising incidence across diverse populations. It encompasses a wide spectrum of malignant diseases characterized by uncontrolled cell growth and potential metastasis. Predominant interventions include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although advances such as immune checkpoint inhibitors and molecularly targeted agents have improved outcomes for some patients, significant challenges persist. Resistance to standard therapies, adverse side effects, and tumor heterogeneity contribute to ongoing unmet clinical needs. VHH-P712’s dual-targeting modality addresses these challenges by potentially enhancing tumor specificity, minimizing off-target toxicity, and enlisting the immune system against otherwise refractory cancers. Its innovative mechanism positions it as a highly promising candidate for next-generation cancer therapeutics.